These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 20404384)
21. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
22. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439 [No Abstract] [Full Text] [Related]
23. Is Jupiter also a god of primary prevention? Accad M; Fred HL Tex Heart Inst J; 2010; 37(1):6-7. PubMed ID: 20200621 [No Abstract] [Full Text] [Related]
24. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials". Vos E; Rose CP; Biron P Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369 [No Abstract] [Full Text] [Related]
25. [JUPITER study (2). For now no reason to give statins to more people]. Koopmans RP Ned Tijdschr Geneeskd; 2009 Feb; 153(6):218-9. PubMed ID: 19271439 [No Abstract] [Full Text] [Related]
26. Statins: how far have we come? A review of rosuvastatin. Olsson A Int J Clin Pract Suppl; 2003 Oct; (137):15-25. PubMed ID: 14649698 [No Abstract] [Full Text] [Related]
27. [JUPITER study, more reason to give statins as preventive measure - commentary]. Narkiewicz K Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067 [No Abstract] [Full Text] [Related]
28. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068 [TBL] [Abstract][Full Text] [Related]
30. [Comment from the family practice viewpoint]. Coradi B Praxis (Bern 1994); 2009 Feb; 98(3):131. PubMed ID: 19180439 [No Abstract] [Full Text] [Related]
31. Rosuvastatin in patients undergoing hemodialysis. Kassimatis TI; Konstantinopoulos PA N Engl J Med; 2009 Jul; 361(1):93; author reply 94-5. PubMed ID: 19579277 [No Abstract] [Full Text] [Related]
32. [Treat the primary cause of inflammation in overweight individuals without symptoms of coronary disease]. Persson J Lakartidningen; 2009 Jun 24-Jul 7; 106(26-27):1758. PubMed ID: 19736661 [No Abstract] [Full Text] [Related]
33. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit. Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361 [No Abstract] [Full Text] [Related]
34. [Less vascular risk with rosuvastatin in elevated CRP]. Bredie B Ned Tijdschr Geneeskd; 2009 Feb; 153(6):245. PubMed ID: 19271446 [No Abstract] [Full Text] [Related]
35. Rosuvastatin in patients with elevated C-reactive protein. Jenny-Avital ER N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275 [No Abstract] [Full Text] [Related]
38. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Ridker PM; Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996 [No Abstract] [Full Text] [Related]